Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets for high-quality clinical trials have been recognised as robust and ...

People living with inflammatory bowel disease (IBD) have new hope, with clinical trials beginning for a breakthrough treatment for one of the most ...

The partnership will integrate PhaseV's adaptive clinical trial technology with Alimentiv's comprehensive GI CRO services.

Researchers from The Institute of Cancer Research in London have developed a new test that can predict colorectal cancer risk ...

PhaseV, a pioneer in software and machine learning (ML) for clinical trial optimization, announced today it has entered a ...

Inflammatory bowel diseases (IBDs), which include ulcerative colitis (UC) and Crohn’s disease (CD), are chronic conditions ...

Gastrointestinal-focused CRO Alimentiv is upgrading its clinical trials with software firm PhaseV’s adaptive trial technology ...

Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

Study urges industry to be more transparent and fairer in selecting speakers, and to recruit more women to steering ...

A groundbreaking test can now predict colorectal cancer risk in IBD patients with over 90 accuracy offering a less invasive ...

The Crohn’s & Colitis Foundation and the American Gastroenterological Association (AGA) are excited to host the annual Crohn’s & Colitis Congress®, taking place Feb. 6-8, in San Francisco, CA. This ...